230962-35-3

Upstream product

• 5002-26-6 3-methyl-4-phenylbromobenzene 
• 98-80-6 phenylboronic acid 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 230962-36-4 5-(3-methyl-4-phenylphenyl)-5-oxopentanoic acid 
• 230962-32-0 5-(3-methyl-4-phenylphenyl)pentanoic acid 
• 230962-33-1 5-(3-methyl-4-phenylphenyl)pentanoyl chloride 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 108-55-4 glutaric anhydride, 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 230962-34-2 4-(S)-benzyl-3-{5-(3-methyl-4-phenylphenyl)pentanoyl}oxazolidin-2-one 

Downstream Products

• 230961-47-4 (2R)-N₁-[(1S)-2,2-dimethyl-1-({[(1S)-2-methoxy-1-phenylethyl]amino}carbonyl)propyl]-2-{3-(3-methyl-4-phenylphenyl)propyl}-(N₄-3-propenyloxy)butanediamide 
• 230962-37-5 (R)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)-pentanoic acid 

Relevant academic research and scientific papers

A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers

The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col

Matrix metalloprotease inhibitors

Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors